

Protocol for the Sampling and Analysis of Finished Marijuana Products and Marijuana Products for Marijuana Establishments, Medical Marijuana Treatment Centers, and Colocated Marijuana Operations

Exhibit 6. Analysis Requirements for Microbiological Contaminants and Mycotoxins in Medical Marijuana Products^a

Implemented March 11, 2021 and Revised June 2, 2021

This document is issued by the Cannabis Control Commission. The applicable Marijuana laws, which include M.G.L. c. 94I, 94G, 935 CMR 500.000 and 935 CMR 501.000, should be reviewed as they may provide or clarify the legal requirements related to this document. This protocol document should be checked periodically for revisions. Questions with regards to this document may be directed to CCCMass.com.



Cannabis Material	Total Viable Aerobic Bacteria (CFU/g)	Total Yeast and Mold (CFU/g)	Total Coliforms (CFU/g)	Bile-tolerant Gram- negative Bacteria (CFU/g)	E Coli (pathogenic strains) and Salmonella spp.	Mycotoxins b
Unprocessed Materials ^c	10 ⁵	104	10 ³	10 ³	Not detected in 1 g	<20 µg of any mycotoxin per kg of material
Processed Materials ^c	105	104	10 ³	10 ³		
CO ₂ and Solvent- based Extracts	104	10 ³	10 ²	10 ²		

CFU: colony forming unit

Please note that these Protocols are continually evaluated and revised based upon new scientific and industry information.



^a Except for mycotoxins, analysis requirements are based on AHP (2013).

^b Mycotoxins include aflatoxin B1, aflatoxin B2, aflatoxin G1, aflatoxin G2, and Ochratoxin A.

^c Unprocessed materials include minimally processed crude cannabis preparations such as inflorescences, accumulated resin glands (kief), and compressed resin glands (hashish). Processed materials include various solid or liquid infused edible preparations, oils, topical preparations, and water-processed resin glands ("bubble hash") (AHP, 2013).